Prospective outcome of early intervention for individuals at ultra-high-risk for psychosis

Early Intervention in Psychiatry

Volumn 2, Issue 4, 2008, Pages 277-284

  Shim, Geum Sook ^a   Kang, Do Hyung ^a   Choi, Jung Seok ^a   Jung, Myung Hun ^a   Kwon, Soo Jin ^a   Jang, Go Eun ^a   Kwon, Jun Soo ^a  

^a Seoul National University   (South Korea)

Author keywords

Antipsychotic agents; Early intervention; Prodromal symptoms; Schizophrenia; Ultra high risk

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; LORAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; ZIPRASIDONE;

ADOLESCENT; ADULT; AKATHISIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; EARLY INTERVENTION; FEMALE; FUNCTIONAL ASSESSMENT; GYNECOMASTIA; HIGH RISK PATIENT; HUMAN; HYPERPROLACTINEMIA; IRRITABILITY; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SECONDARY AMENORRHEA; SEDATION; SIDE EFFECT; SOCIAL INTERACTION; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65249136984     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2008.00089.x     Document Type: Article

References (45)

1. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785-804.
2. Norman RM, Lewis SW, Marshall M. Duration of untreated psychosis and its relationship to clinical outcome. Br J Psychiatry 2005; 187 (Suppl. 48): 19-23.
3. Tsuang MT, Stone WS, Faraone SV. Towards the prevention of schizophrenia. Biol Psychiatry 2000; 48: 349-56.
4. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58: 158-64.
5. Miller TJ, McGlashan TH, Rosen JL et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: Preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002; 159: 863-5.
6. Yung AR, Phillips LJ, Yuen HP et al. Psychosis prediction: 12-month follow up of a high-risk ('prodromal') group. Schizophr Res 2003; 60: 21-32.
7. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: The Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005; 39: 964-71.
8. Phillips LJ, Yung AR, Yuen HP, Pantelis C, McGorry PD. Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. Am J Med Genet 2002; 114: 929-37.
9. Falloon IR. Early intervention for first episodes of schizophrenia: A preliminary exploration. Psychiatry 1992; 55: 4-15.
10. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-8.
11. McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-9.
12. Morrison AP, French P, Parker S et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 2007; 33: 682-7.
13. Woods SW, Breier A, Zipursky RB et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003; 54: 453-64.
14. Häfner H, Maurer K, Ruhrmann S et al. Early detection and secondary prevention of psychosis: Facts and visions. Eur Arch Psychiatry Clin Neurosci 2004; 254: 117-28.
15. Ruhrmann S, Bechdolf A, Kühn KU et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry 2007; 191 (Suppl. 51): 88-95.
16. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. New York: Biometrics Research Department, 1996.
17. Maxwell ME. Manual for the Family Interview for Genetic Studies (FIGS). Bethesda, MD: Clinical Neurogenetics Branch, Intramural Research Program, National Institute of Mental Health, 1992.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
19. McGorry PD, Goodwin RJ, Stuart GW. The development, use, and reliability of the brief psychiatric rating scale (nursing modification) - an assessment procedure for the nursing team in clinical and research settings. Compr Psychiatry 1988; 29: 575-87.
20. Andreasen NC. The Scale of the Assessment of Positive Symptoms. Iowa City: University Of Iowa, 1984.
21. Andreasen NC. The Scale of the Assessment of Negative Symptoms. Iowa City: University of Iowa, 1983.
22. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-96.
23. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5.
24. Goodman WK, Price LH, Rasmussen SA et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-11.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
26. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry 1990; 157: 853-9.
27. Kim JS, Lee YS. Validity of Short Forms of the Korean-Wechsler Adult Intelligence Scale. Korean. J Clin Psychol 1995; 14: 111-6.
28. Schultze-Lutter F. Prediction of psychosis is necessary and possible. In: McDonald C, Schulze K, Murray R, Wright P, eds. Schizophrenia: Challenging the Orthodox. London, New York: Taylor & Francis, 2004; 81-90.
29. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: Psychopathology and clinical features. Schizophr Res 2004; 67: 131-42.
30. Amminger GP, Leicester S, Yung AR et al. Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals. Schizophr Res 2006; 84: 67-76.
31. Cohen J. Statistical Power Analysis for the Behavioral Sciences, revised edn. Hillsdale, NJ: Lawrence Erlbaum, 1988.
32. Cornblatt BA, Auther AM. Treating early psychosis: Who, what, and when? Dialogues Clin Neurosci 2005; 7: 39-49.
33. Phillips LJ, McGorry PD, Yuen HP et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 2007; 96: 25-33.
34. World Health Organization. An International Follow-up Study. Chichester(UK): Wiley, 1979.
35. Mosher LR. The Soteria Project: The first generation American alternatives to psychiatric hospitalization. In: Warner R, ed. Alternatives to Hospital for Acute Psychiatric Treatment. Washington: American Psychiatric Press, 1995; 111-29.
36. Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull 1980; 6: 606-18.
37. Lehtinen V, Aaltonen J, Koffert T, Räkköläinen V, Syvälahti E. Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed? Eur Psychiatry 2000; 15: 312-20.
38. Warner R. Problems with early and very early intervention in psychosis. Br J Psychiatry 2005; 187 (Suppl. 48): 104-7.
39. Chung YS, Kang D-H, Shin NY, Yoo SY, Kwon JS. Deficit of theory of mind in individuals at ultra-high-risk for schizophrenia. Schizophr Res 2008; 99: 111-8.
40. Ruhrmann S, Schultze-Lutter F, Maier W, Klosterkötter J. Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry 2005; 20: 1-6.
41. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: A neurodevelopmental perspective. Schizophr Bull 2003; 29: 633-51.
42. Yung AR, Yuen HP, Berger G et al. Declining transition rate in ultra high risk (prodromal) services: Dilution or reduction of risk? Schizophr Bull 2007; 33: 673-81.
43. Payne J, Malla A, Norman R, Windell D, Nicole B. Status of first-episode psychosis patients presenting for routine care in a defined catchment area. Can J Psychiatry 2006; 51: 42-7.
44. Fennig S, Rabinowitz J. Involuntary first admission of patients with schizophrenia as a predictor of future admissions. Psychiatr Serv 1999; 50: 1049-52.
45. Cornblatt BA, Lencz T, Smith CW et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007; 68: 546-57.